I feel this is the new NASH700 way to approval strategy; don't let the FDA send us into another slow walk extended trial, submit the numbers of “Efficacy and safety of Leronlimab” to other experts and doctors in the field and have them get excited.

Big Pharma will take notice as soon as experts in any given area have a buzz and we will get a partner or buyout right away. The FDA route just becomes "we can keep this drug off the market for at least another 3 years" so you guys can keep pushing your Remdesivir.